Trial ID 20172 | Maryland Oncology Hematology Trial ID 20172 – Maryland Oncology Hematology

Trial ID 20172

Trial Information - Phase I/II

A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer

Protocol ID: SGN22E-002

Sponsor: Seagen, Inc.

Status: COHORT CLOSED

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at 877-664-7724

Disease Types

Urothelial

Investigator

Min MD, Frederick

Status

COHORT CLOSED

Sponsor

Seagen, Inc.

Quality Care Close to Home


View our locations on map!

Sign Up Today For Our E-Newsletter

  • This field is for validation purposes and should be left unchanged.
United in Healing with The US Oncology Network - Maryland Oncology Hematology